143 related articles for article (PubMed ID: 38022398)
1. Clinicopathological Characteristics and Prognosis of Triple-Negative Apocrine Carcinoma: A Case-Control Study.
Suzuki C; Yamada A; Kawashima K; Sasamoto M; Fujiwara Y; Adachi S; Oshi M; Wada T; Yamamoto S; Shimada K; Ota I; Narui K; Sugae S; Shimizu D; Tanabe M; Chishima T; Ichikawa Y; Ishikawa T; Endo I
World J Oncol; 2023 Dec; 14(6):551-557. PubMed ID: 38022398
[TBL] [Abstract][Full Text] [Related]
2. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
3. AMACR Expression is a Potential Diagnostic Marker in Apocrine Lesions of Breast, and is Associated with High Histologic Grade and Lymph Node Metastases in Some Invasive Apocrine Breast Cancers.
Lerner G; Tang H; Singh K; Golestani R; St Claire S; Humphrey PA; Lannin D; Janostiak R; Harigopal M
Clin Breast Cancer; 2023 Feb; 23(2):199-210. PubMed ID: 36577560
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.
Iwase H; Kurebayashi J; Tsuda H; Ohta T; Kurosumi M; Miyamoto K; Yamamoto Y; Iwase T
Breast Cancer; 2010 Apr; 17(2):118-24. PubMed ID: 19466512
[TBL] [Abstract][Full Text] [Related]
5. Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy.
Montagna E; Cancello G; Pagan E; Bagnardi V; Munzone E; Dellapasqua S; Viale G; Mazzarol G; Veronesi P; Galimberti V; Santomauro G; Colleoni M
Breast; 2020 Oct; 53():138-142. PubMed ID: 32795829
[TBL] [Abstract][Full Text] [Related]
6. Tumor-infiltrating lymphocytes status, programmed death-ligand 1 expression, and clinicopathological features of 41 cases of pure apocrine carcinoma of the breast: a retrospective study based on clinical pathological analysis and different immune statuses.
Xiao X; Jin S; Zhangyang G; Xiao S; Na F; Yue J
Gland Surg; 2022 Jun; 11(6):1037-1046. PubMed ID: 35800740
[TBL] [Abstract][Full Text] [Related]
7. Pure Apocrine Carcinomas Represent a Clinicopathologically Distinct Androgen Receptor-Positive Subset of Triple-Negative Breast Cancers.
Mills AM; E Gottlieb C; M Wendroth S; M Brenin C; Atkins KA
Am J Surg Pathol; 2016 Aug; 40(8):1109-16. PubMed ID: 27259012
[TBL] [Abstract][Full Text] [Related]
8. [Clinical characteristics comparison between triple-negative and non-triple-negative breast cancer].
Zhang HM; Xuan LX; Gao JD; Zhang BN; Zhao P
Zhonghua Wai Ke Za Zhi; 2009 Apr; 47(7):506-10. PubMed ID: 19595207
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological characteristics and prognostic marker of triple-negative breast cancer in older women.
Honma N; Ogata H; Yamada A; Matsuda Y; Kontani K; Miyashita M; Arai T; Sasaki E; Shibuya K; Mikami T; Sawaki M
Hum Pathol; 2021 May; 111():10-20. PubMed ID: 33548251
[TBL] [Abstract][Full Text] [Related]
10. Potential prognostic tumor biomarkers in triple-negative breast carcinoma.
Peng Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Oct; 44(5):666-72. PubMed ID: 23073572
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean Population.
Lim S; Park SH; Park HK; Hur MH; Oh SJ; Suh YJ
PLoS One; 2015; 10(11):e0140208. PubMed ID: 26562837
[TBL] [Abstract][Full Text] [Related]
13. Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype.
Yi SY; Ahn JS; Uhm JE; Lim DH; Ji SH; Jun HJ; Kim KH; Chang MH; Park MJ; Cho EY; Choi YL; Park YH; Im YH
BMC Cancer; 2010 Oct; 10():527. PubMed ID: 20920367
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological Characteristics of Triple-negative Breast Cancers in the Northeast Region of Turkey.
Yıldız B; Fidan E; Ozdemir F; Sezen O; Kavgacı H; Aydın F
Balkan Med J; 2014 Jun; 31(2):126-31. PubMed ID: 25207183
[TBL] [Abstract][Full Text] [Related]
15. [Clinicopathological characteristics and prognosis of different molecular types of breast cancer].
Liu ZF; Chen C; Yao XL; Sun SR
Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1733-7. PubMed ID: 27356638
[TBL] [Abstract][Full Text] [Related]
16. Triple-negative apocrine carcinoma as a rare cause of a breast lump in a Syrian female: a case report and review of the literature.
Ismail S; Kherbek H; Skef J; Zahlouk N; Abdulal R; Alshehabi Z
BMC Womens Health; 2021 Nov; 21(1):396. PubMed ID: 34823507
[TBL] [Abstract][Full Text] [Related]
17. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18.
Fisher ER; Wang J; Bryant J; Fisher B; Mamounas E; Wolmark N
Cancer; 2002 Aug; 95(4):681-95. PubMed ID: 12209710
[TBL] [Abstract][Full Text] [Related]
18. Triple-Negative Apocrine Breast Carcinoma Has Better Prognosis despite Poor Response to Neoadjuvant Chemotherapy.
Hu T; Liu Y; Wu J; Hu XL; Zhao G; Liang B; Wang S; Long M
J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329934
[TBL] [Abstract][Full Text] [Related]
19. Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations.
Bergeron A; MacGrogan G; Bertaut A; Ladoire S; Arveux P; Desmoulins I; Bonnefoi H; Loustalot C; Auriol S; Beltjens F; Degrolard-Courcet E; Charon-Barra C; Richard C; Boidot R; Arnould L
Mod Pathol; 2021 Jul; 34(7):1282-1296. PubMed ID: 33753865
[TBL] [Abstract][Full Text] [Related]
20. Avoidance and Period-Shortening of Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer in Stages I and II: Importance of Ki-67 Labeling Index and the Recognition of Apocrine-Type Lesions.
Kubouchi K; Shimada K; Yokoe T; Tsutsumi Y
Technol Cancer Res Treat; 2020; 19():1533033820943246. PubMed ID: 32677589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
